Why the study?
Australia reports high rates of clozapine-associated myocarditis amid rapid titration, prompting a follow-up audit to evaluate titration-relevant risk factors.
What are the risk factors for clozapine-associated myocarditis in patients commencing clozapine therapy?
What are the risk factors for clozapine-associated myocarditis in patients commencing clozapine therapy?
Clozapine-associated myocarditis is associated with risk factors that impact clozapine metabolism, suggesting that slower, personalized titration may reduce adverse cardiac events.
No takes yet. Share an insight, caveat, or question.
Case series of CAM supports heightened monitoring in rapid-titration settings; leaves open optimal prevention protocols.
Carswell et al. (2023) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: